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components of CP or treated as covariates. Because CP are active both on organiza-
tional (units) and individual (patients) level, a two-arm cluster Randomized Controlled 
Trial with hospitals and long-term rehabilitation facilities as randomization units was 
designed in phase II. Fourteen units were randomized either to arm 1 (CP) or to arm 
2 (usual care) including 238 patients per group. The primary outcome measure was 
mortality, the CP were also analyzed with key quality indicators. The trial has been 
successfully performed (phase III) and in-hospital mortality has been reduced (OR = 
0.10; P = 0.04). Because the adjusted results are not available yet, it was not possible 
to identify the active components of the CP and therefore phase IV has not been 
performed. CONCLUSIONS: Even if the results are still partial, it seems possible to 
apply this framework to the study of CP. 
DIABETES/ENDOCRINE DISORDERS – Clinical Outcomes Studies
PDB1
CLINICAL OUTCOMES WITH DPP4 INHIBITORS IN SINGAPORE
Narayanaswamy S, Goh LF, Yip WL
Singapore General Hospital, Singapore
OBJECTIVES: 1) Compare efﬁ cacy and safety of sitagliptin and vildagliptin in type 
2 diabetes; and 2) Examine prescription of concomitant oral hypoglycemic agents 
(OHAs) and insulin. METHODS: We conducted a retrospective database study, 
drawing information from all patients treated at Singapore Health Services cluster 
institutions over 1.5-year study period. Inclusion criteria: HbA1C >7%, naive to 
gliptins, and remained on gliptin for at least 90 days (from pharmacy records). Exclu-
sion criteria: patients who switched gliptins, and HbA1c not tested within 10 days of 
exit timepoint. IRB approval was obtained. RESULTS: Sitagliptin (n = 340) and 
vildagliptin (n = 92) patients met inclusion and exclusion criteria. General demograph-
ics matched at baseline (all P > 0.05). Mean duration of gliptin treatment 242 days 
(sitagliptin) versus 220 days (vildagliptin) (P = 0.944). Mean baseline HbA1c matched 
at 8.95% (sitagliptin) versus 9.18% (vildagliptin) (P = 0.15). At exit, sitagliptin arm 
demonstrated absolute HbA1c reduction of −0.643% versus vildagliptin −0.728% (P 
= 0.61); percentage reduction in HbA1c was sitagliptin −6.55% versus vildagliptin 
−7.589% (p = 0.44). Subgroup analyses of a) patients with entry HbA1c >8%; b) 
stratiﬁ cation of outcome by dose of gliptin; and c) addition or discontinuation of OHA 
from baseline all did not demonstrate statistically signiﬁ cant difference. Majority of 
patients were not on maximal OHA doses at gliptin initiation, however total daily 
doses of OHAs was not signiﬁ cantly different at exit versus baseline for both arms. 
Almost 90% of patients in both groups received multiple OHAs for diabetes control. 
Change in creatinine clearance was comparable in both arms. Safety endpoints micro-
albuminuria/creatinine ratio, average % weight change and incidence of pancreatitis 
were not signiﬁ cantly different between both arms (all P > 0.05). Five sitagliptin 
patients required hospital admission for severe hypoglycemia vs 0 vildagliptin patients. 
CONCLUSIONS: We present our initial ﬁ ndings that vildagliptin is non-inferior to 
sitagliptin in HbA1c-lowering efﬁ cacy. Both products are well-tolerated without sig-
niﬁ cant differences in safety endpoints save severe hypoglycemia in sitagliptin arm. 
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OBJECTIVES: To evaluate the long-term health outcomes associated with Liraglutide 
1.2 and 1.8 mg versus Glimepiride 4 mg all combined with Metformin in Asian 
patients with type 2 diabetes (T2D). METHODS: A published and validated computer 
simulation model of diabetes (CORE Diabetes Model) was used to make the projection 
of long-term health outcomes (30 years). Simulated cohorts and treatment effects were 
derived from 928 T2D patients in the NCT00614120 trial held in China, South Korea 
and India. HbA1C was signiﬁ cantly reduced in Liraglutide 1.2 mg, Liraglutide 1.8 mg, 
and Glimepiride groups (−1.3%, −1.4%, and −1.3% respectively). Liraglutide treat-
ments led to greater reduction in Body Mass Index and systolic blood pressure versus 
Glimepride. No major hypoglycemia was reported in Liraglutide groups, while the 
rate of major hypoglycemia for Glimepride was 0.029 per patient-year. The rate of 
minor hypoglycemia was lower in Liraglutide groups than Glimepiride. An annual 
discounting rate of 3% was used for health and cost outcomes. One-way sensitivity 
analysis was performed. RESULTS: The treatments of Liraglutide compared with 
Glimepiride were projected to reduce the cumulative incidences of diabetes complica-
tions and improve long term health outcomes for patients with T2D. For Liraglutide 
1.2 mg, the cumulative incidences of background retinopathy, end stage renal disease, 
ulcer, and congestive heart failure event were reduced 0.20%, 0.086%, 0.020% and 
0.53% respectively, discounted life expectancy was increased 0.058 year and quality 
adjusted life-years (QALY) was increased 0.11 QALY. For Liraglutide 1.8mg, the 
incidences reduction were 0.61%, 0.12%, 0.34% and 0.63% respectively, discounted 
life expectancy was improved 0.051 year, and 0.107 QALY. CONCLUSIONS: Lira-
glutide 1.2 mg and 1.8 mg therapy could delay the onset of diabetes complications 
and reduced related cumulative incidences over patient lifetimes compared with 
Glimepiride. It improved the life expectancy and quality adjusted life expectancy in 
Asian patients with T2D. 
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OBJECTIVES: To address effects of extended-release versus immediate-release glipi-
zide on glucose control, insulin secretion, and compliance. METHODS: We included 
parallel randomized trials and cohort studies (only for compliance assessment) com-
paring extended-release versus immediate-release glipizide for type 2 diabetes. We 
searched Medline, EMBASE, the Cochrane Library, and Chinese Biomedical database, 
screened reference lists, and contacted pharmaceutical company. We pooled data using 
random-effect model and explored heterogeneity by pre-speciﬁ ed hypotheses. 
RESULTS: Sixteen trials involving 1062 patients and two retrospective cohort studies 
of 13,452 patients were included. Trials are of inadequate quality. No trials reported 
patient-important outcomes. The reduction of fasting plasma glucose from the baseline 
appeared larger in extended-release than immediate-release glipizide (mean difference 
−0.30 mmol/L, 95% CI −0.57 to −0.03). The reduction was not signiﬁ cant different 
between two drugs in HbA1c (−0.03%, −0.20% to 0.15%) and 2-hour postprandial 
plasma glucose (−0.28 mmol/L, −1.12 to 0.55). Extended-release glipizide appeared 
to reduce insulin secretion from the baseline, whereas immediate-release formulation 
increased the secretion (fasting insulin: −0.86 vs. 0.28 μIU/ml; 2-hour postprandial 
insulin: −2.94 vs. 0.24 μIU/ml). Patients administering extended-release glipizide had 
less hypoglycemia (Peto odds ratio 0.26, 95% CI 0.08 to 0.81) and lower missed 
dosing (Peto odds ratio 10.24, 95%CI 5.22 to 20.08). The cohort studies showed 
results in compliance consistent with trials. CONCLUSIONS: The two drugs may 
have comparable effects on glucose control. Extended-release glipizide might achieve 
glucose control with decreased insulin secretion, and fewer hypoglycemic episodes. 
The ﬁ ndings are inconclusive due to inadequate study quality, short follow-up, and 
unavailability of patient important outcomes. 
DIABETES/ENDOCRINE DISORDERS – Cost Studies
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OBJECTIVES: To assess overall and diabetes-related medical service costs associated 
with pioglitazone (PIO) and sulfonylureas (SU) treatment among T2DM patients. 
METHODS: This is a retrospective cohort study based on electronic medical records 
(January 1, 2004–January 31, 2009) from the Geisinger Clinic in the Northeastern 
region of the United States. The date of the initial prescription for PIO or SU was 
denoted as the index date. Patients were required to be aged 18 years or older and 
prescribed an oral antidiabetic treatment in the 1 year prior to index. Patients with 
type 1 or gestational diabetes and prior insulin use were excluded, as were those who 
had prescriptions for the index drug in the 90 days prior. Propensity score 1:1 match-
ing and a second stage of generalized linear regression were employed to assess overall 
and diabetes-related medical service costs (pharmacy costs were not available in the 
database) in the 2 years following the index date, adjusting for patient demographics, 
baseline comorbidities, medication use, and health-care resource utilization. RESULTS: 
A total of 2758 patients, 1379 each in the PIO and SU cohorts, were analyzed. For 
both cohorts, mean age was 62 years, 46% were male, and 96% were Caucasian. The 
two cohorts were similar in terms of current smoking status and diabetes-related 
comorbidities. The unadjusted total and diabetes-related medical costs were $1258 
and $705 higher for SU versus PIO patients. After adjusting for covariates, the overall 
and diabetes-related medical service costs remained higher for patients receiving SU 
versus PIO ($8360 vs. $7400 for overall, and $5577 vs. $5238 for diabetes-related 
costs, P < 0.05 for both comparisons). CONCLUSIONS: Over a 2-year follow-up, 
patients with T2DM initiated on PIO therapy in an integrated system incurred lower 
overall and diabetes-related medical service costs than patients initiated on SU. Further 
studies describing clinical and humanistic aspects of PIO versus SU are warranted. 
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OBJECTIVES: To estimate annual health-care costs associated with hypoglycemia 
among T2DM patients initiated on oral antidiabetic drugs (OADs) in a large managed 
care cohort with managed care insurance beneﬁ ts. METHODS: T2DM patients initi-
ated on OADs were selected from the Ingenix Impact database (1999–2008). Patients 
aged 18 years or older with at least 1 year of continuous eligibility following the index 
date (the ﬁ rst OAD prescription ﬁ ll date) who were diagnosed with moderate to severe 
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hypoglycemia events (ICD-9-CM 250.8×, 251.0×, 251.1×, 251.2×) were identiﬁ ed. 
Annual total, medical, pharmacy, and diabetes-related costs for patients with or 
without the diagnosis of hypoglycemia were compared during the 12-month post-
index period. Diabetes-related medical costs included all non-pharmacy costs associ-
ated with T2DM diagnosis. Generalized linear regressions with robust standard error 
accounting for skewed cost distribution were performed, adjusting for demographics, 
comorbidities, and OADs. RESULTS: A total of 212,061 T2DM patients with at least 
one OAD treatment were identiﬁ ed. Among them, 4860 (2.29%) had a hypoglycemia 
diagnosis during the ﬁ rst year following the index date. Patients with hypoglycemia 
had signiﬁ cantly higher average annual total costs ($18,273 vs. $8908, P < 0.001) and 
diabetes-related total costs ($8969 vs. $3220, P < 0.001) than those without hypogly-
cemia. After adjusting for confounding factors, hypoglycemia patients had signiﬁ -
cantly higher incremental annual total costs and diabetes-related total costs than 
patients without hypoglycemia ($5031 and $3751, respectively, both P < 0.001). 
Similar trends were observed for annual medical costs and diabetes-related medical 
costs ($4967 and $3796, respectively, both P < 0.001). CONCLUSIONS: Hypogly-
cemia in type 2 diabetes patients initiated with OADs in a large US managed care 
setting is associated with signiﬁ cantly higher total, medical, and diabetes-related costs 
compared with those who did not experience hypoglycemia. 
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OBJECTIVES: This study was to examine the prevalence and economic burden of in 
patients with diabetes and/or related complications from Tingyi hospital in Wuhan 
China. METHODS: This was a retrospective analysis focused on hospitalization costs 
and complications for all patients diagnosed with diabetes and administered in Wuhan 
Tingyi hospital in China from June 2007 to December 2007. All information of patient 
demographic characters, clinical and costs were collected for the analysis. The descrip-
tive statistics was used to describe patients’ demographic characters, duration of the 
diseases and treatment costs. RESULTS: There were total of 295 inpatients were 
included in the study. The mean age of patients was 51.6 ± 16.0 years (range 11–87 
years), 53.56% were male. The diabetes durations (±SD) were 5.75 ± 6.04 years. 
13.56% were type 1 diabetes, and 86.44% were type 2 diabetes. The mean hospital 
stay (±SD) were 11.99 days (±0.54), and mean of hospitalization costs (±SD) were 
USD 876.6 (±39.4) (1US$ = 7.6 RMB). The patients with no complication, micro 
vascular complications, macro vascular complications or both were 10.20%, 30.27%, 
8.16%, and 51.36% respectively. Peripheral neuropathy (69.2%) and hyperlipidemia 
(64.1%) were of the highest prevalence among all the complications, and diabetic foot 
ulcer was the expensive complication with the highest treatment costs (USD657). The 
costs of tests and medications accounted for 27% and 26% of total hospitalization 
expenses. Anti–diabetes drugs, complication treatments and other drugs were of 
37.7%, 52.8%, and 9.4% respectively in the medication costs. CONCLUSIONS: 
Most of hospitalized patients had diabetes complications. Diabetic complications 
contributed to a substantial economic burden for the patients and society. It implied 
the urgent need for health-care policymakers to address this issue by adopting effective 
measures toward prevention and control of diabetes and its complications. 
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BACKGROUND: Growth hormone replacement therapy (GHRT) is an expensive 
health service excluded from the universal coverage (UC) beneﬁ t package of Thailand. 
Its high costs and exclusion from the UC beneﬁ t package prevent poor patients from 
access to such health care. OBJECTIVES: This study aims to estimate costs of provid-
ing GHRT to patients diagnosed with growth hormone deﬁ ciency (GHD). It also 
explores demand for, and supply of, and total costs per unit of height increase from 
universal access to GHRT. METHODS: Methods include comprehensive literature 
review, in-depth interviews of childhood endocrinologists from three university hos-
pitals about costs of GHRT and its current practice, and modeling costs for height 
increase using different products. RESULTS: Research ﬁ ndings indicate the incidence 
of GHD in Thailand is approximately 1 to 50,000 of people aged less than 15 years. 
A weekly dosage of GHRT recommended by the Thai Pediatric Endocrine Society 
range from 0.1 to 0.3 mg per kg depending on patient’s responses. Cessation criteria 
of GHRT comprise 1) attainment of adult height at 165 and 155 cm in male and 
female, respectively; 2) bone age above 16 and 14 years in male and female respec-
tively; and 3) the annual increase of height lower than 2.5 cm. On supply side, 
approximately 40 pediatric endocrinologists are available in public and private settings 
across the country. Costs of GHRT are varied from factors including patient’s age 
and gender, type and dose of GH use. Data from a university hospital show costs of 
GHRT range from $950 to $2580 per every 1 cm of height increase when using a 
cheaper GH product. The costs will increase from $1460 to $4000 per every 1 cm of 
height increase when using the original GH. CONCLUSIONS: High cost burden of 
GHRT poses a challenging question on whether it should be included in the UC beneﬁ t 
package. 
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OBJECTIVES: To evaluate the long-term health outcomes and economic consequences 
of the treatment of Insulin Detemir (IDet) in type 2 diabetes patients switching from 
insulin Glargine (IGla) in the setting of Chinese urban hospitals. METHODS: A 
published and validated computer simulation model of diabetes (the CORE Diabetes 
Model) was used to make the long- term (30 years) projection of health economic 
outcomes. The patient demographic information and clinical endpoints were derived 
from the PREDICTIVE subgroup study. The study was a large, multi-center, 6 months 
observational study assessing the safety and efﬁ cacy of IDet in everyday clinical 
practice. HbA1c was reduced of −0.59% by switching from IGla to IDet. Baseline risk 
factors and racial characteristic data were obtained from Chinese cohort studies. The 
market retail prices of medications were calculated to estimate treatment costs. The 
diabetes management and complications costs were obtained from Chinese published 
data and adjusted to 2009 values using the Chinese Consumer Price Index. An annual 
discounting rate of 3% was used for both health and cost outcomes. One-way sensi-
tivities analysis was performed and illustrated that the results were robust. RESULTS: 
The treatment of IDet converted from IGla was projected to reduce the cumulative 
incidences of Eye disease, Renal disease, Ulcer, Cardiovascular disease, Cataract, End-
Stage Renal Disease, Ulcer, Neuropathy, Myocardial Infarction events were reduced 
0.293%, 0.151%, 0.794%, 3.293%, 1.225% respectively. Patients’ time alive and 
free of complication was improved 0.15 year. Patient life expectancy was increased 
by 0.09 year and 0.36 quality adjusted life-year (QALY) when converting to IDet. 
The costs of complications were reduced by 4931 CNY (89,628 vs. 94,559), resulting 
in a total direct medical cost saving of 684 CNY. CONCLUSIONS: The treatment of 
IDet improved patient health and economic outcomes, and was a cost-saving treatment 
approach in a Chinese setting. 
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OBJECTIVES: To estimate the long term clinical and cost outcomes of continuous 
subcutaneous insulin infusion (CSII) compared with multiple daily injections (MDI) 
of insulin in adult type 1 diabetes mellitus (T1DM) patients from a third party payer 
perspective in China. METHODS: A previously validated computer simulation model 
of diabetes (CORE Diabetes Model) was used to estimate the long-term clinical and 
cost consequences of CSII to MDI in the Chinese consumer-use setting and to calculate 
the incremental cost-effectiveness ratio (ICER). Clinical and cost data as well as treat-
ment effects and patient characteristics were obtained from previously published 
studies. Costs and clinical projections were made over patient lifetimes from a third-
party payer perspective and discounted at 3% annually. The primary input variable 
was change in HbA1c and was assumed to be an improvement of −1.2% for CSII 
compared with MDI. RESULTS: CSII was associated with improvements of 1.037 in 
quality adjusted life-years (QALYs) gained and 0.963 life-years gained per patient 
versus MDI. CSII was associated with an incremental cost-effectiveness ratio (ICER) 
of CNY 214,988 per QALY gained for CSII versus MDI. Improved glycemic control 
from CSII led to a lower incidence of lifetime diabetes complications; with the most 
signiﬁ cant reductions in proliferative diabetic retinopathy (PDR; a 29% reduction), 
end stage renal disease (ESRD; a 22% reduction) and peripheral vascular disease 
(PVD; a 15% reduction). CSII was associated with increased direct lifetime medical 
costs of Chinese Yuan (CNY) 222,994 per patient compared to MDI. CONCLU-
SIONS: For type 1 diabetes patients in China, CSII (consumer-use) would be consid-
ered cost-effective assuming a willingness-to-pay threshold of CNY 235,000 per 
QALY gained. 
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OBJECTIVES: The LEAP is a multidisciplinary management program (including 
angioplasty, bypass surgery and medical treatment) designed to enhance limb salvage 
for patients with diabetes and critical limb ischemia (CLI). This study aims to deter-
mine the cost-effectiveness of the LEAP strategy compared with the pre-LEAP strategy 
(standard practice) for treating patients with diabetes and CLI. METHODS: Clinical 
data relating to 277 patients in the LEAP were collected from 2001 until 2005. 
Comparative data were retrospectively collected for 144 patients with diabetes and 
CLI referred to the hospital in 2000. A lack of follow-up data in the pre-LEAP group 
restricted this study to the inpatient period. Signiﬁ cance of differences in therapeutic 
